Objective
The client is one of the top global manufacturers of oncology products wanted to forecast Advanced NSCLC and GC Market with focus on main aspects as below,
- Develop insights on epidemiology of advanced NSCLC and GC indications including incidence, prevalence, drug treatable patient by segments
- Emerging target gene and MOA with clinical stage of development
- Future treatment algorithm capturing emerging biomarker and MOA
- Patients and sales forecast by histology, biomarker, and MOA
Approach
A comprehensive approach has been designed to get in-depth understanding of the NSCLC and GC market in EU5, US, China, Japan along with future implications.
eQuantX developed a comprehensive forecast model and independent Advanced NSCLC and GC Market insight reports from a series of data-gathering and insight-generation events supported by our unique network of global key opinion leaders and specialists (eGlobalPMR)
- Forecast inputs were derived from deep dives with 40+ key opinion leaders and other stakeholders discussing and debating the current and future clinical landscape, treatment paradigms, management of lung cancer patients, drug development, and other insights
- The patient shares for the pipeline products will be estimated based on the target biomarker (%), line of therapy and launch sequence by country. For the uptake of the biomarker targeted products, a hybrid uptake curve of the erlotinib, gefitinib (except US) and crizotinib is considered. Specific launch sequence of the product by country will be considered
- Common factors considered for peak share estimation of pipeline: -Efficacy parameters (PFS, OS and ORR), safety (Grade ¾, SAE), order of entry, presence of mutations or resistance in previous line of therapy, line of therapy, being evaluated (1st, 2nd, 3rd, etc.), pricing/ annual cost of therapy, compliance (dosage formulation, dosage frequency and country type) etc.
Outcome
Using insights from the forecast model and insight’s reports, our client was able to build successful product sales projections, revenue analysis and long-term planning.
The client leveraged eQuantX forecasting platform which provide better handling of real-time patient level data as well as the often-complex patient journey through therapy.
The report provided the relevant information required to build the strategy for their new product development and commercialization, and an expert overview of the current and future treatment landscape, competitor’s analysis and management of patients.
Strategic insights specific to the client’s product were also included, highlighting the current market is likely to evolve based on factors such as patient population growth, key market events, innovations in development, emerging competitor products, and changing payer positions, government policy and standards of care
